Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research

Rockville, MD, April 2, 2017 –  Precision-Biologics Inc. today announced an abstract reporting data on the company’s neo-antigen program has been accepted for an oral presentation at the upcoming 110th Annual Meeting of the American Association of Clinical...

Cancer Breakthroughs 2020: The Nation’s First Neoepitope Antibody Immunotherapy Phase II Trial Demonstrating Safety and Prolonged Survival in Patients with Metastatic End-Stage Colon Cancer October 31, 2016

Embed from Getty Images Clinical investigators from Moffitt and Walter Reed Army Institute present data of first Phase II Neoepitope Antibody Immunotherapy Clinical Trial completed at John’s Hopkins, Duke and Moffitt as a potential new immunotherapy treatment for...